Experimental HIV Drugs
Experimental HIV Drugs
IAS 2013: Dolutegravir Superior to Raltegravir for Treatment-experienced People with HIV
- Details
- Category: Experimental HIV Drugs
- Published on Wednesday, 03 July 2013 00:00
- Written by Liz Highleyman
The once-daily HIV integrase inhibitor dolutegravir demonstrated better efficacy than twice-daily raltegravir for previously treated people with HIV, with fewer study withdrawals due to virological failure and less emergent drug resistance, researchers reported at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) this week in Kuala Lumpur. Results were published concurrently in the July 3, 2013, online edition of The Lancet.
New NRTI BMS-986001 Potently Suppresses HIV in Early Monotherapy Study
- Details
- Category: Experimental HIV Drugs
- Published on Wednesday, 19 June 2013 00:00
- Written by Liz Highleyman
BMS-986001, a novel thymidine nucleoside reverse transcriptase inhibitor (NRTI) being developed by Bristol-Myers Squibb, demonstrated good antiviral activity and appeared safe and well-tolerated in a 10-day monotherapy study, researchers reported in the July 1, 2013, Journal of Acquired Immune Deficiency Syndromes.
FDA Declines Approval of Elvitegravir and Cobicistat as Stand-alone HIV Meds
- Details
- Category: HIV Treatment
- Published on Tuesday, 07 May 2013 00:00
- Written by Liz Highleyman
The U.S. Food and Drug Administration (FDA) has rejected approval of Gilead Sciences' integrase inhibitor elvitegravir and pharmacoenhancer cobicistat -- components of the 4-in-1 Stribild quad pill -- as single agents for treatment of HIV, the company announced last week.
Cobicistat Booster Is a Safe and Effective Alternative to Ritonavir
- Details
- Category: Experimental HIV Drugs
- Published on Thursday, 30 May 2013 00:00
- Written by Liz Highleyman
The novel pharmacoenhancer cobicistat boosts blood levels of atazanavir (Reyataz) as well as ritonavir (Norvir) and is generally safe and well-tolerated over 48 weeks, according to final study results published in the July 1, 2013, Journal of Infectious Diseases.
CROI 2013: MK-1439 -- A Novel NNRTI For HIV Treatment [VIDEO]
- Details
- Category: HIV Treatment
- Published on Friday, 15 March 2013 00:00
- Written by Gregory Fowler
A next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI), MK-1439, demonstrated good antiretroviral activity and tolerability as 7-day monotherapy in a small Phase 1b trial, researchers reported at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) last week in Atlanta.
More Articles...
- CROI 2013: Challenges and Opportunities for the Development of Long-acting Antiretrovirals [VIDEO]
- CROI 2013: Dolutegravir Helps Highly-resistant Treatment-experienced People on Failing ART
- CROI 2013: New Antiretroviral Agents: Cenicriviroc [VIDEO]
- CROI 2013: CCR5/CCR2 Inhibitor Cenicriviroc Has Both Anti-HIV and Anti-inflammatory Effects
Web Design and Development by